Table 4.
Odds Ratios for CD4 Proliferative Response to HCV Core, NS3-4, and NS5 Proteins in Patients Positive for HLA DQB1*03, DRB1*1, or DRB3*02 Relative to Ethnicity
| All Patients (n = 73) | White Patients (n = 27) | Black Patients (n = 46) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Core | NS3-4 OR (P-value) |
NS5 | N | Core | NS3-4 OR (P-value) |
NS5 | N | Core | NS3-4 OR (P-value) |
NS5 | |
| DQB1*03 | 42 | 4.5 (0.048) | 1.9 (0.264) | 1.7 (0.336) | 18 | 10.0 (0.071)b | 4.0 (0.363) | 2.3 (0.636) | 24 | 2.0 (0.67) | 1.4 (0.62) | 1.7 (0.43) |
| DRB1*11 | 21 | 3.1 (0.191) | 1.7 (0.366) | 2.6 (0.090) | 7 | 4.3 (0.290) | 7.6 (0.050) | 25.3 (0.009) | 14 | 2.6 (0.35) | 0.7 (0.73) | 1.0 (1.00) |
| DRB3*02 | 34 | 2.7 (0.127) | 1.9 (0.250) | 3.0 (0.049) | 8 | 8.5 (0.044) | 14.2 (0.011) | 18.0 (0.017) | 26 | 1.6 (0.68) | 0.7 (0.60) | 1.3 (0.67) |
| DQB1*03-DRB3*02 | 24 | 5.6 (0.015) | 3.2 (0.033) | 3.7 (0.018) | 8 | 8.5 (0.044) | 14.2 (0.011) | 18.0 (0.017) | 16 | 4.7 (0.16) | 1.5 (0.73) | 2.0 (0.33) |
| DRB1*11-DRB3*02 | 20 | 3.4 (0.077) | 1.8 (0.283) | 2.9 (0.075) | 7a | 4.3 (0.290) | 7.6 (0.050) | 25.3 (0.009) | 13 | 3.0 (0.33) | 0.8 (1.00) | 1.2 (1.00) |
| DQB1*03-DRB1*11 | 19 | 3.7 (0.067) | 2.0 (0.235) | 3.2 (0.062) | 7a | 4.3 (0.290) | 7.6 (0.050) | 25.3 (0.009) | 12 | 3.4 (0.17) | 0.9 (1.00) | 1.4 (0.72) |
| DQB1*03-DRB1*11- DRB3*02 |
18 | 4.1 (0.060) | 2.3 (0.215) | 3.6 (0.055) | 7a | 4.3 (0.290) | 7.6 (0.050) | 25.3 (0.009) | 11 | 4.0 (0.14) | 1.1 (1.00) | 1.7 (0.70) |
Odds ratios (OR) with respective P-values in parentheses were calculated by chi-squared or Fisher’s exact test. Only patients with genotype 1 or serotype 1 infection are included. HCV-specific CD4 T cell response with stimulation index > 3.0 was considered positive.
a
All of the white patients who carried the DRB1*11 allele (n = 11) also carried DQB1*03 and DRB3*02.
b
OR was Haldane-Woolf adjusted.